Aclaris Therapeutics, Inc. — Director's Dealing 2021

Sep 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-09-01

Reporting Person: Monahan Joseph (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-01	Common Stock	M	2333	—	Acquired	87675	Direct
2021-09-01	Common Stock	F	1041	$17.22	Disposed	86634	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Restricted Stock Units	$	M	2333	Disposed		Common Stock (2333)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	193	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

F3: The shares underlying these restricted stock units vested on September 1, 2021.